Cibus, Inc. announced its financial results for the fourth quarter ended December 31, 2024. The company reported a net loss of $28.4 million for the quarter, compared to a net loss of $26.9 million in Q4 2023. Revenue for Q4 2024 was $0.9 million, up from $0.5 million in Q4 2023.
The company highlighted several operational advancements, including progress in its rice herbicide tolerance trait commercialization efforts and the successful editing of a fourth mode of action for Sclerotinia resistance in canola. Cibus also announced an AI-powered gene discovery partnership with Biographica.
Peter Beetham, Interim CEO, stated that opportunities for gene-edited traits are materializing, with herbicide tolerance traits in Rice generating commercial interest across multiple markets. The company also noted positive regulatory progress, including the California Rice Commission's approval of Cibus's field research proposal for gene-edited rice.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.